Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
TARS
TARS
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TARS News
Tarsus Pharmaceuticals Q4 2025 Earnings Call Highlights
Feb 24 2026
seekingalpha
Tarsus Pharmaceuticals Reports Narrowed Losses in 2025 Financials
Feb 24 2026
NASDAQ.COM
Tarsus Pharmaceuticals Q4 Earnings Analysis
Feb 23 2026
seekingalpha
Tarsus Pharmaceuticals Appoints New Board Member
Feb 18 2026
Newsfilter
From Olema to Insmed: Do These Soaring Biotechs Still Present a Good Investment Opportunity?
Nov 19 2025
NASDAQ.COM
Tarsus Pharmaceuticals, Inc. (TARS) Posts Q3 Loss but Exceeds Revenue Projections
Nov 05 2025
NASDAQ.COM
Tarsus Sets Q4 Sales Goal of $140M–$145M Amidst Increased XDEMVY Adoption and Pipeline Development
Nov 04 2025
SeekingAlpha
HC Wainwright & Co. Reaffirms Buy Rating for Tarsus Pharmaceuticals and Increases Price Target to $88
Oct 20 2025
Benzinga
Noteworthy TARS Put and Call Options Set for November 21st
Sep 19 2025
NASDAQ.COM
Tarsus Set to Join Upcoming Investor Conferences
Aug 27 2025
Newsfilter
Two Health Care Stocks at Risk of Significant Decline This August
Aug 20 2025
Benzinga
Frazier Life Sciences Closes Oversubscribed $1.3 Billion Venture Fund
Jul 31 2025
Newsfilter
Tarsus Pharmaceuticals Becomes Oversold (TARS)
Jun 17 2025
NASDAQ.COM
TARS Makes Bullish Cross Above Critical Moving Average
Jun 06 2025
NASDAQ.COM
Tarsus to Participate in Upcoming Investor Conferences
May 29 2025
Newsfilter
HC Wainwright & Co. Assumes Tarsus Pharmaceuticals at Buy, Announces Price Target of $72
May 27 2025
Benzinga
Show More News
